Garban F, et al. - Given pathogen reduction of platelet concentrates may reduce transfusion-transmitted infections but is associated with qualitative impairment, which could have clinical significance with regard to platelet hemostatic capacity, researchers herein compared the efficacy of platelets in additive solution treated with amotosalen–UV-A vs untreated platelets in plasma or in additive solution in patients with thrombocytopenia and hematologic malignancies. They found noninferior hemostatic efficacy of pathogen-reduced platelets in thrombopenic patients with hematologic malignancies, compared with platelets in additive solution. However, comparison between pathogen-reduced platelets and platelets in plasma did not reveal such noninferiority.